Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02947685 · OUTCOME

3 and 5 Year Survival Probabilities

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · Source last updated 2026-02-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients alive
Interval / dispersion
95% Confidence Interval
Time frame
5 years

What was measured

Defined as the percentage of patients still alive and followed at 3 and 5 years post beginning of treatment.

Groups in this outcome

Arm A

Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)

Arm B

AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A261
Arm B257

Reported measurements

At 3 years
Values in percentage of patients alive · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm A87Not reported82.891.2Not reported
Arm B84.7Not reported8089.3Not reported
At 5 years
Values in percentage of patients alive · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm A72.9Not reported6679.7Not reported
Arm B68.5Not reported61.176Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        82.8
        upper Limit
        91.2
        value
        87
      2. group Id
        OG001
        lower Limit
        80
        upper Limit
        89.3
        value
        84.7
    title
    At 3 years
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        66
        upper Limit
        79.7
        value
        72.9
      2. group Id
        OG001
        lower Limit
        61.1
        upper Limit
        76
        value
        68.5
    title
    At 5 years
denoms
  1. counts
    1. group Id
      OG000
      value
      261
    2. group Id
      OG001
      value
      257
    units
    Participants
description
Defined as the percentage of patients still alive and followed at 3 and 5 years post beginning of treatment.
dispersion Type
95% Confidence Interval
groups
  1. description
    Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)
    id
    OG000
    title
    Arm A
  2. description
    AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)
    id
    OG001
    title
    Arm B
param Type
NUMBER
reporting Status
POSTED
time Frame
5 years
title
3 and 5 Year Survival Probabilities
type
SECONDARY
unit Of Measure
percentage of patients alive

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice